On Saturday at the Huntington Study Group Meeting in Houston, Roche/Genentech announced the US and Canadian locations for their Natural History Study. This study does not involve drug treatments. It will monitor people with early manifest Huntington’s disease by testing their symptoms and measuring their mutant huntingtin levels over time. It will last for 16…

HDSA-supported researcher Dr. Amber Southwell is featured this week in an article about huntingtin-lowering. Her lab’s recent publication showed that an antisense oligonucleotide (ASO) designed to lower mutant huntingtin improved cognitive and behavioral problems in HD mice. Dr. Southwell was a 2015 HD Human Biology Fellow, and with HDSA’s support was able to transition to…

This week, we have opened up applications for HDSA research funding. Learn about how we support HD research and pass it on these opportunities to the scientists in your life! 2019 Berman/Topper Family HD Career Development Fellowship The Huntington’s Disease Society of America (HDSA) believes we must ensure that the pipeline of passionate and bright…

This week, we announced the winners of the 2018 HD Human Biology Fellowship. These young scientists were chosen for their well-designed projects that focus on understanding Huntington’s disease as it occurs in humans. Below are their names and the basic questions they will focus on in their HD research.  Rossana Foti, University of Copenhagen, Denmark:…

HDSA received hundreds of questions during and after the September 26th webinar presented by Genentech/Roche representatives about upcoming clinical trials. We thank you for your patience as we prepared responses to your frequently asked questions with input from Genentech/Roche. This FAQ document can be accessed on our website at the following link: https://hdsa.org/wp-content/uploads/2018/10/FINAL-101518_FAQ-about-Upcoming-Roche-Studies_for-HDSA.pdf Thanks again…

ASOs therapies have dominated the news recently, but did you know that there are many additional strategies being developed in HD labs for huntingtin lowering? PhD student Julia Alterman will give a webinar next week about a method for interfering with huntingtin RNA and how she is testing it in animal models of HD. Julia…

When symptoms of HD start before the age of 20, this is known as juvenile onset Huntington’s disease, or JHD. A team in Italy led by Dr. Fernando Squitieri did a large analysis of data from big studies like REGISTRY and ENROLL, comparing JHD with adult HD and revealing new insights into how Huntington’s affects…

If you missed the clinical trials update webinar presented by Roche on Wednesday the 26th, it’s now available for viewing on HDSA’s youtube channel and will be uploaded to our website shortly. In this webinar, four Roche team members, J.P. Sacksteder, Mai-Lise Nguyen, Erik Lundgren, and Dr. Scott Schobel, provided a clear community update on…

This past Sunday at the plenary meeting of the European Huntington’s Disease Network (EHDN), Roche Pharmaceuticals announced some details about two upcoming clinical trials. This scientific presentation in Vienna was followed by a Community Statement from Roche/Genentech to HD families worldwide that HDSA shared via our website, social media, and email. In summary, Roche will…

This week, members of the HDSA team are attending the 2018 plenary meeting of the European Huntington’s Disease Network (EHDN) in Vienna, Austria. Alongside the latest findings from HD researchers worldwide, Ionis Pharmaceuticals and Roche/Genentech will continue to present the results from the successful safety trial of their huntingtin-lowering ASO. The HD research community is…